Skip to contentP
Palvella Therapeutics, Inc.
P
PVLAPalvella Therapeutics, Inc. Q4 2023 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$1.30M$1.30Mderived−77.8% vs Q4 2022 Net Income$38.65M$38.65MderivedN/M vs Q4 2022 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Palvella Therapeutics, Inc. · CIK 1583648 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived$13,386,000N/M Operating Cash Flowderived$20,447,000N/M Free Cash Flowderived$20,460,000N/M Margins · derivedOperating margin1030.5%+1227.5 pt vs Q4 2022
Net margin2975.4%+3114.0 pt vs Q4 2022
ended Dec 31, 2023 · filed Mar 29, 2024 · 89 d after period end